## Giorgio Maria Saracco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/148439/publications.pdf

Version: 2024-02-01

206 papers 6,981 citations

76294

h-index

71651 76 g-index

206 all docs 206 docs citations

206 times ranked 6658 citing authors

#	Article	IF	CITATIONS
1	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology, 1991, 180, 842-848.	1.1	641
2	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 2011, 54, 1208-1216.	3.6	399
3	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	6.3	345
4	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
5	Comparing Attendance and Detection Rate of Colonoscopy With Sigmoidoscopy and FIT for Colorectal Cancer Screening. Gastroenterology, 2007, 132, 2304-2312.	0.6	241
6	Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointestinal Endoscopy, 2004, 60, 513-519.	0.5	227
7	Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology, 1993, 105, 845-850.	0.6	190
8	Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. Journal of the National Cancer Institute, 2005, 97, 347-357.	3.0	178
9	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- $\hat{1}\pm2b$ . Hepatology, 1993, 18, 1300-1305.	3.6	149
10	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. Journal of Hepatology, 2018, 69, 301-307.	1.8	126
11	Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology, 1999, 117, 161-166.	0.6	120
12	Covered metal stents for management of inoperable malignant colorectal strictures. Gastrointestinal Endoscopy, 2000, 52, 735-740.	0.5	116
13	Narrow-Band Imaging for Detection of Neoplasia at Colonoscopy: A Meta-analysis of Data From Individual Patients in Randomized Controlled Trials. Gastroenterology, 2019, 157, 462-471.	0.6	113
14	A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Medica, 2016, 58, 304-317.	0.2	111
15	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology, 1989, 10, 336-341.	3.6	96
16	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology, 1991, 13, 413-416.	3.6	96
17	Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; Persistence of anti–hepatitis C virus in children is associated with the mother's anti–hepatitis C virus immunoblotting pattern. Hepatology, 1995, 21, 328-332.	3.6	91
18	Incidence of Type 2 Diabetes Mellitus and Glucose Abnormalities in Patients With Chronic Hepatitis C Infection by Response to Treatment: Results of a Cohort Study. American Journal of Gastroenterology, 2008, 103, 2481-2487.	0.2	86

#	Article	IF	Citations
19	Significant improvement of glycemic control in diabetic patients with HCV infection responding to directâ€acting antiviral agents. Journal of Medical Virology, 2018, 90, 320-327.	2.5	80
20	Irritable bowel syndrome: the clinical approach. Panminerva Medica, 2018, 60, 213-222.	0.2	80
21	Natural History of Perinatal Hepatitis C Virus Infection. Clinical Infectious Diseases, 1996, 23, 47-50.	2.9	77
22	Risk of Post-Transfusion Infection with the Hepatitis Delta Virus. New England Journal of Medicine, 1985, 312, 1488-1491.	13.9	76
23	AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. Journal of Hepatology, 2007, 46, 1026-1033.	1.8	73
24	Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial. American Journal of Gastroenterology, 1999, 94, 2246-2250.	0.2	72
25	Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology, 1995, 22, 1374-1378.	3.6	71
26	Serologic Markers with Fulminant Hepatitis in Persons Positive for Hepatitis B Surface Antigen. Annals of Internal Medicine, 1988, 108, 380.	2.0	67
27	Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Medica, 2019, 110, 95-100.	0.3	66
28	Helicobacters and Extragastric Diseases. Helicobacter, 2009, 14, 58-68.	1.6	65
29	Digestive Endoscopy Is Not a Major Risk Factor for Transmitting Hepatitis C Virus. Annals of Internal Medicine, 2005, 142, 903.	2.0	63
30	Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial. Hepatology, 1998, 28, 341-346.	3.6	57
31	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. Digestive and Liver Disease, 2016, 48, 105-111.	0.4	54
32	Liver fibrosis: the 2017 state of art. Panminerva Medica, 2017, 59, 320-331.	0.2	53
33	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. Journal of Clinical Medicine, 2019, 8, 1646.	1.0	50
34	Sequence variation in hepatitis C viral isolates. Journal of Hepatology, 1991, 13, S6-S14.	1.8	49
35	Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. World Journal of Gastroenterology, 2016, 22, 8187.	1.4	49
36	A randomized 4-arm multicenter study of interferon alfa–2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology, 2001, 34, 133-138.	3.6	48

#	Article	IF	Citations
37	Fatal multiple systemic embolisms after injection of cyanoacrylate in bleeding gastric varices of a patient who was noncirrhotic butÂwith idiopathic portal hypertension. Gastrointestinal Endoscopy, 2007, 65, 345-347.	0.5	47
38	Preliminary experience with a new cytology brush in EUS-guided FNA. Gastrointestinal Endoscopy, 2009, 70, 1220-1224.	0.5	46
39	Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scandinavian Journal of Gastroenterology, 2019, 54, 407-413.	0.6	46
40	HCV genotypes in patients with liver disease of different stages and severity. Journal of Hepatology, 1997, 26, 1173-1178.	1.8	43
41	Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. Journal of Hepatology, 1997, 27, 56-62.	1.8	42
42	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	2.0	42
43	Fecal calprotectin: beyond intestinal organic diseases. Panminerva Medica, 2018, 60, 29-34.	0.2	41
44	Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. Journal of Clinical Medicine, 2019, 8, 199.	1.0	40
45	Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterologica E Dietologica, 2018, 64, 310-321.	2.2	39
46	Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Patients with Post-Liver Transplant Biliary Complications: Results of a Cohort Study with Long-Term Follow-Up. Gut and Liver, 2011, 5, 328-334.	1.4	39
47	Recent advances in the treatment of irritable bowel syndrome. Polish Archives of Internal Medicine, 2021, 131, 709-715.	0.3	36
48	Impact of viral eradication with sofosbuvirâ€based therapy on the outcome of postâ€transplant hepatitis C with severe fibrosis. Liver International, 2017, 37, 62-70.	1.9	35
49	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Medica, 2017, 59, 283-289.	0.2	35
50	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scandinavian Journal of Gastroenterology, 2018, 53, 734-740.	0.6	34
51	Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology, 2019, 11, 489-512.	0.8	34
52	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 3941.	1.0	34
53	A Practical Guide to the Use of Interferons in the Management of Hepatitis Virus Infections. Drugs, 1997, 53, 74-85.	4.9	30
54	Progressive Increase of Matrix Metalloprotease-9 and Interleukin-8 Serum Levels during Carcinogenic Process in Human Colorectal Tract. PLoS ONE, 2012, 7, e41839.	1.1	30

#	Article	IF	Citations
55	Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. Liver Transplantation, 2002, 8, 630-635.	1.3	29
56	The Natural History of Gastrointestinal Subepithelial Tumors Arising From Muscularis Propria. Journal of Clinical Gastroenterology, 2009, 43, 821-825.	1.1	29
57	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 800.	1.0	29
58	Self-expanding covered esophageal Ultraflex stent for palliation of malignant colorectal anastomotic obstruction complicated by multiple fistulas. Gastrointestinal Endoscopy, 2000, 51, 346-348.	0.5	28
59	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers, 2020, 12, 3218.	1.7	27
60	The role of microbiota in autism spectrum disorders. Minerva Gastroenterologica E Dietologica, 2018, 64, 333-350.	2.2	27
61	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology, 2002, 36, 959-966.	3.6	26
62	High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. Journal of Hypertension, 2009, 27, 102-108.	0.3	26
63	Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn�s disease: an observational study. Revista Espanola De Enfermedades Digestivas, 2020, 112, 195-200.	0.1	26
64	Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Digestive Diseases and Sciences, 2002, 47, 401-404.	1.1	25
65	Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. Journal of Hepatology, 2003, 38, 455-460.	1.8	25
66	Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured?. American Journal of Gastroenterology, 2006, 101, 1811-1816.	0.2	25
67	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers, 2021, 13, 2305.	1.7	24
68	Evaluation of Clensia $\hat{A}^{\otimes}$ , a new low-volume PEG bowel preparation in colonoscopy: Multicentre randomized controlled trial versus 4L PEG. Digestive and Liver Disease, 2017, 49, 651-656.	0.4	23
69	Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. Medicines (Basel, Switzerland), 2020, 7, 33.	0.7	23
70	Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography. European Journal of Gastroenterology and Hepatology, 2012, 24, 70-76.	0.8	22
71	Usefulness of the index of <scp>NASH</scp> – <scp>ION</scp> for the diagnosis of steatohepatitis in patients with nonâ€alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	1.9	22
72	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. International Journal of Molecular Sciences, 2020, 21, 8838.	1.8	22

#	Article	IF	Citations
73	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Medica, 2019, 110, 401-409.	0.3	22
74	Histologic Changes in Liver Biopsy Specimens Produced by Recombinant Interferon <i>α</i> -2b Therapy for Chronic Non-A,Non-B Viral Hepatitis: <i>A Randomized Controlled Trial</i> . American Journal of Clinical Pathology, 1992, 98, 397-401.	0.4	21
75	The long-term efficacy of interferon alfa in chronic hepatitis C patients: A critical review. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 668-673.	1.4	21
76	Successful closure of a postsurgical benign esophagomediastinal fistula by temporary placement of a polyester, expandable stent: Case report and review. Gastrointestinal Endoscopy, 2002, 56, 747-750.	0.5	21
77	Hepatitis B coreâ€related antigen kinetics in chronic hepatitis B virus genotype Dâ€infected patients treated with nucleos(t)ide analogues or pegylatedâ€interferonâ€Î±. Hepatology Research, 2017, 47, 747-754.	1.8	20
78	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 1323.	1.0	20
79	Predictors of response to interferon therapy. Digestive Diseases and Sciences, 1996, 41, 115S-120S.	1.1	19
80	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. Journal of Clinical Medicine, 2020, 9, 2353.	1.0	18
81	The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. Journal of Clinical Medicine, 2020, 9, 563.	1.0	18
82	Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology, 1995, 22, 1374-1378.	3 <b>.</b> 6	18
83	Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies?. Minerva Cardioangiologica, 2016, 64, 686-96.	1.2	18
84	Autoimmune hepatitis or drugâ€induced autoimmune hepatitis following Covidâ€19 vaccination?. Liver International, 2022, 42, 1204-1205.	1.9	18
85	Hepatitis C virus infection and disease. Journal of Hepatology, 1993, 17, S78-S82.	1.8	17
86	Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. American Journal of Gastroenterology, 2008, 103, 1966-1972.	0.2	17
87	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. Minerva Medica, 2017, 108, 489-495.	0.3	17
88	The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scandinavian Journal of Gastroenterology, 2018, 53, 141-146.	0.6	16
89	Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators. European Journal of Surgical Oncology, 2018, 44, 1873-1879.	0.5	16
90	Risk of drug interactions and prescription appropriateness in elderly patients. Irish Journal of Medical Science, 2020, 189, 953-959.	0.8	16

#	Article	IF	Citations
91	Differential diagnosis of pancreatic cysts: A prospective study on the role of intra-cystic glucose concentration. Digestive and Liver Disease, 2020, 52, 1026-1032.	0.4	16
92	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. Journal of Clinical Medicine, 2021, 10, 3387.	1.0	16
93	Helicobacter pylori and Respiratory Diseases: 2021 Update. Microorganisms, 2021, 9, 2033.	1.6	16
94	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. Journal of Advanced Research, 2021, 33, 183-187.	4.4	16
95	Primary liver cancer is of multifactorial origin: Importance of hepatitis B virus infection and dietary aflatoxin. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 604-608.	1.4	15
96	Prevalence of Non-Organ-Specific Autoantibodies in Patients Suffering from Duodenal Ulcer With and Without Helicobacter pylori Infection. Digestive Diseases and Sciences, 2004, 49, 395-398.	1.1	15
97	Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study. Digestive and Liver Disease, 2012, 44, 406-412.	0.4	15
98	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
99	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- $\hat{l}\pm2b$ . Hepatology, 1993, 18, 1300-1305.	3.6	15
100	Longâ€term followâ€up of diabetic and nonâ€diabetic patients with chronic hepatitis C successfully treated with directâ€acting antiviral agents. Liver International, 2021, 41, 276-287.	1.9	15
101	Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers, 2022, 14, 828.	1.7	15
102	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: A randomised trial. Digestive and Liver Disease, 2014, 46, 803-807.	0.4	14
103	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers, 2020, 12, 2776.	1.7	14
104	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114985.	0.8	14
105	Endoscopic Ultrasound-Guided Treatments for Non-Variceal Upper GI Bleeding: A Review of the Literature. Journal of Clinical Medicine, 2020, 9, 866.	1.0	14
106	Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. Clinical and Diagnostic Virology, 1994, 1, 289-297.	1.8	13
107	Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?. Journal of Medical Virology, 2008, 80, 628-631.	2.5	13
108	Comparison of complication rates between endoscopic and fluoroscopic percutaneous gastrostomies. Nutrition, 2001, 17, 967-968.	1.1	12

#	Article	IF	CITATIONS
109	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Lithuania), 2019, 55, 441.	0.8	12
110	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Digestive and Liver Disease, 2022, 54, 1101-1108.	0.4	12
111	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 635.	1.0	12
112	Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis. European Journal of Gastroenterology and Hepatology, 2011, 23, 573-577.	0.8	11
113	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.4	11
114	Gastroenterology today: between certainties and news. Minerva Gastroenterologica E Dietologica, 2018, 64, 323-332.	2.2	11
115	HLAâ€DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 39-44.	0.9	11
116	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. Medicina (Lithuania), 2020, 56, 285.	0.8	11
117	Management of functional dyspepsia in 2020: a clinical point of view. Minerva Gastroenterologica E Dietologica, 2021, 66, 331-342.	2.2	11
118	Eosinophilic colitis: clinical review and 2020 update. Minerva Gastroenterologica E Dietologica, 2020, 66, 157-163.	2.2	11
119	Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Current Oncology, 2022, 29, 1422-1429.	0.9	11
120	Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C–positive recipients. Liver Transplantation, 2017, 23, 915-924.	1.3	10
121	Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives. Journal of Clinical Medicine, 2020, 9, 3535.	1.0	10
122	Chronic active hepatitis B. Interferonâ€activated natural killerâ€like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. Liver, 1991, 11, 106-113.	0.1	9
123	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. Digestive and Liver Disease, 2015, 47, 405-410.	0.4	9
124	Favorable shortâ€ŧerm outcome of hepatitis C virus–positive liver graft with bridging fibrosis: A plea for very early viral eradication. Hepatology, 2017, 65, 2116-2118.	3.6	9
125	Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology, 2019, 54, 1233-1236.	0.6	9
126	Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. Current Oncology, 2021, 28, 1034-1044.	0.9	9

#	Article	IF	Citations
127	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, .	0.3	9
128	Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. Revista Espanola De Enfermedades Digestivas, 2019, 112, 59-63.	0.1	9
129	The small intestine: barrier, permeability and microbiota. Key messages for clinicians. Minerva Gastroenterology, 2020, , .	0.3	9
130	Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy. Balkan Medical Journal, 2017, 34, 290-291.	0.3	9
131	Inflammatory Bowel Disease Nurseâ€"Practical Messages. Nursing Reports, 2021, 11, 229-241.	0.8	8
132	Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 4961.	1.0	8
133	Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without Helicobacter pylori infection. Minerva Biotechnology and Biomolecular Research, 2017, 29, .	0.3	7
134	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. Expert Review of Molecular Diagnostics, 2018, 18, 467-475.	1.5	7
135	Peripheral neuropathy after viral eradication with directâ€acting antivirals in chronic HCV hepatitis: A prospective study. Liver International, 2021, 41, 2611-2621.	1.9	7
136	Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. Panminerva Medica, 2021, 63, 332-335.	0.2	7
137	Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. Minerva Biotecnologica, 2019, 31, .	1.2	7
138	Treatment with interferon- $\hat{1}\pm2b$ of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. European Journal of Gastroenterology and Hepatology, 2001, 13, 149-155.	0.8	6
139	Prospective randomized trial: Endoscopic follow up 3 vs 6months after esophageal variceal eradication by band ligation in cirrhosis. European Journal of Internal Medicine, 2014, 25, 674-679.	1.0	6
140	Efficacy of infliximab biosimilars in patients with Crohn's disease. Lancet, The, 2017, 390, 2435-2436.	6.3	6
141	Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. Scandinavian Journal of Gastroenterology, 2019, 54, 1339-1345.	0.6	6
142	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. Digestive and Liver Disease, 2021, 53, 712-716.	0.4	6
143	Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021. Journal of Clinical Medicine, 2021, 10, 1313.	1.0	6
144	Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. Journal of Clinical Medicine, 2021, 10, 3308.	1.0	6

#	Article	IF	CITATIONS
145	Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video). Endoscopic Ultrasound, 2017, 6, 416.	0.6	6
146	Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA. Clinical Laboratory, 2018, 64, 411-412.	0.2	6
147	Proctitis: a glance beyond inflammatory bowel diseases. Minerva Gastroenterologica E Dietologica, 2020, 66, 252-266.	2.2	6
148	Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 9156-9168.	1.3	6
149	Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. Journal of Hepatology, 1994, 21, 278-279.	1.8	5
150	Interferon in chronic hepatitis B. Antiviral Research, 1994, 24, 137-143.	1.9	5
151	Basic and clinical aspects of resistin. Minerva Biotecnologica, 2018, 30, .	1.2	5
152	Is there a link between periampullary diverticula and biliopancreatic disease? An EUS approach to answer the question. Digestive and Liver Disease, 2018, 50, 925-930.	0.4	5
153	Wait-and-See Policy for a Small Pancreatic Schwannoma Diagnosed With Endoscopic Ultrasound With Fine-Needle Aspiration. ACG Case Reports Journal, 2019, 6, e00139.	0.2	5
154	The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. Minerva Gastroenterology, 2021, 67, 264-272.	0.3	5
155	Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. Minerva Gastroenterologica E Dietologica, 2019, 65, 11-19.	2.2	5
156	Assessment of glomerular filtration rate in patients with cirrhosis: Available tools and perspectives. Liver International, 2022, , .	1.9	5
157	Hepatitis B $x$ antigen and polymerase antibodies in the serum of hepatitis B carriers with or without hepatitis delta virus infection. Journal of Hepatology, 1992, 14, 286-293.	1.8	4
158	Durability of the response to peginterferon- $\hat{l}\pm2b$ and ribavirin in patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2014, 26, 52-58.	0.8	4
159	Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3Âcm. Medical Oncology, 2016, 33, 104.	1.2	4
160	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease?. Obesity Surgery, 2018, 28, 550-551.	1.1	4
161	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. Journal of Hepatology, 2019, 70, 793-795.	1.8	4
162	An unpleasant souvenir: Endoscopic finding of Trichuris trichiura (Nematoda: Trichuridae). Parasitology International, 2021, 80, 102220.	0.6	4

#	Article	IF	CITATIONS
163	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology, 2021, 10, 215.	1.3	4
164	A rare case of gastric fistulization of a main-duct intraductal papillary mucinous neoplasm. Minerva Gastroenterologica E Dietologica, 2018, 64, 383-385.	2.2	4
165	Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?. Biomedicines, 2022, 10, 534.	1.4	4
166	The small intestine: barrier, permeability and microbiota. Minerva Gastroenterology, 2022, 68, .	0.3	4
167	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. Biomedicines, 2022, 10, 792.	1.4	4
168	Gastro-esophageal reflux disease: Key messages for clinicians. Minerva Gastroenterologica E Dietologica, 2020, , .	2.2	4
169	Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. Liver, 1993, 13, 222-226.	0.1	3
170	Adalimumab trough levels predict Crohn's disease clinical course. Digestive and Liver Disease, 2018, 50, 204-206.	0.4	3
171	Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis. Minerva Biotecnologica, 2021, 32, .	1.2	3
172	Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome?. Minerva Pediatrica, 2018, 70, 634-635.	2.6	3
173	Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. Minerva Gastroenterologica E Dietologica, 2019, 65, 77-78.	2.2	3
174	Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score. Minerva Gastroenterologica E Dietologica, 2020, 66, 106-112.	2.2	3
175	The role of topical therapy for perianal fistulizing Crohn's disease: are we forgetting something?. Minerva Gastroenterologica E Dietologica, 2019, 65, 130-135.	2.2	3
176	Screening and surveillance of oesophageal varices in patients with HCVâ€positive liver cirrhosis successfully treated by directâ€acting antiviral agents. Liver International, 2022, , .	1.9	3
177	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, 196-208.	0.3	3
178	Irritable bowel syndrome and lactose intolerance: a challenging overlap. Minerva Gastroenterology, 2021, 67, .	0.3	2
179	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 3257.	1.0	2
180	Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn�s disease. Revista Espanola De Enfermedades Digestivas, 2018, 110, 28-33.	0.1	2

#	Article	IF	CITATIONS
181	Impact of Macroscopic On-Site Evaluation (MOSE) on Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Biopsy (EUS-FNB) of Pancreatic and Extrapancreatic Solid Lesions: A Prospective Study. Diagnostics, 2022, 12, 428.	1.3	2
182	Response to Yeh. American Journal of Gastroenterology, 2009, 104, 1052-1052.	0.2	1
183	Comments on Sulimani et al.: A weekly 35,000ÂIU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females. Archives of Osteoporosis, 2017, 12, 102.	1.0	1
184	Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp― Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-2.	0.8	1
185	Longâ€ŧerm followâ€up of diabetic and nonâ€diabetic patients with chronic hepatitis C. Liver International, 2021, 41, 640-640.	1.9	1
186	Liver involvement in adult-onset Still's disease: our experience in a third level liver unit and review of the literature. Minerva Gastroenterology, 2024, 69, .	0.3	1
187	Long-term benefits of viral clearance on extrahepatic manifestations of hepatitis c virus infection: light at the end of the tunnel?. Minerva Gastroenterology, 2021, 67, 215-217.	0.3	1
188	A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. Life, 2021, 11, 650.	1.1	1
189	The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017. Panminerva Medica, 2017, 59, 199.	0.2	1
190	Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis. Anais Brasileiros De Dermatologia, 2017, 92, 584-584.	0.5	1
191	Irritable bowel syndrome: a real-world picture of the USA. Minerva Gastroenterologica E Dietologica, 2019, 65, 79-81.	2.2	1
192	Diarrhea due to parasites: a short updated point of view from the clinical setting. Minerva Gastroenterology, 2022, , .	0.3	1
193	On elevated alanine aminotransferase in type 1 diabetes mellitus. Minerva Gastroenterologica E Dietologica, 2016, 62, 223.	2.2	1
194	Interferon treatment and ALT normalization concomitant with ongoing viral replication. Hepatology, 1990, 12, 790-791.	3.6	0
195	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology, 2002, 36, 959-966.	3.6	О
196	Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of <i>Helicobacter pylori</i> : A Comparative Study in a Cohort of Romanian Patients― Gastroenterology Research and Practice, 2016, 2016, 1-2.	0.7	0
197	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?― Digestive and Liver Disease, 2016, 48, 1101-1102.	0.4	О
198	Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough?. European Journal of Internal Medicine, 2018, 50, e29-e30.	1.0	0

 #	Article	IF	CITATIONS
199	Seronegative occult hepatitis C virus infection: what is its clinical relevance?. Minerva Biotecnologica, 2021, 32, .	1.2	0
200	Use of reflux finding score and reflux symptom index for the management of laryngopharyngeal lesions: a pilot study. Minerva Gastroenterology, 2021, , .	0.3	0
201	Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms?., 1994,, 261-264.		0
202	Food supplements, stress and gastrointestinal diseases. Panminerva Medica, 2017, 59, 274-275.	0.2	0
203	Finally, it is bismuth's time. Saudi Journal of Gastroenterology, 2017, 23, 127.	0.5	0
204	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq0 0 0 rg	BT./Overlo	ock 10 Tf 50 5
205	Irritable bowel syndrome and lactose intolerance: a challenging overlap. Minerva Gastroenterology, 2021, 67, 67-68.	0.3	O
206	Quantitative data do not coincide with meaningful insights: Reply to Shahreedhan et al Liver International, 2022, 42, 2343-2343.	1.9	0